Ipsen in Brief - Global
Ipsen in Brief
Loading...
  • Mediaarrow_down
      < Back
    • Media
    • Press Releases
    • Media Statements
    • Media Library
  • Investors  arrow_down
    < Back
    • Investors
    • Financial Results
    • Corporate News
    • Financial Calendar
    • Investor Events
    • Reports and Accounts
    • Regulated Information

    • Combined Shareholders’ Meeting 2024 (pre announcement page launch)

       Featured Image
  • Partnering
  • Careersarrow_down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
  • Loading...
  • English  EN     Français  FR     EN  arrow_down
    • EnglishEN
    • FrançaisFR
  • Global Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada EN
    • Canada FR
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Slovakia
    • Czech Republic
    • Austria
    • Switzerland
    • Middle East
  • Home
  • Companyarrow_down
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Sciencearrow_down
      < Back
    • Science
    • Oncology
    • Rare Disease
    • Neuroscience
    • Products
    • R&D
    • Pipeline
    • Clinical Trials
  • Responsibilityarrow_down
      < Back
    • Responsibility
    • Responsibility
    • Environment
    • Patients
    • People
    • Governance
  • Patientsarrow_down
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Lay Summaries
    • Collaborate with us
  • Stories
  1. Home
  2. Reports and Accounts
  3. reports and accounts

Ipsen in Brief

Back

Post navigation

Previous
Next

Ipsen in Brief

A snapshot of Ipsen’s key figures, financial results and Generation Ipsen achievements.

Ipsen in Brief

- 24 April 2023 - 1 mins read

A snapshot of Ipsen’s key figures, financial results and Generation Ipsen achievements.

Post navigation

Previous
Next

Share this on social media

  • Share on LinkedIn
  • Share on Twitter
  • Share on Facebook

Related Reports and Accounts

Global Quality Policy
18 June 2024 0 mins read

Global Quality Policy
EHS Policy
18 June 2024 0 mins read

EHS Policy
ISO 45001-2018
18 June 2024 0 mins read

ISO 45001-2018
ISO 14001-2015
18 June 2024 0 mins read

ISO 14001-2015
Supplier screening
18 June 2024 0 mins read

Supplier screening
Lobbying activities, association management and governance framework for public policy engagement
18 June 2024 0 mins read

Lobbying activities, association management and governance framework for public policy engagement
D E & I achievements for 2023
18 June 2024 0 mins read

D E & I achievements for 2023
Modern Slavery Statement
18 June 2024 0 mins read

Modern Slavery Statement
Human rights position paper
18 June 2024 0 mins read

Human rights position paper
ISO 37001 Certification
18 June 2024 0 mins read

ISO 37001 Certification

IPN price

€113.10

 €1.20 (1.07%)

  • Media
  • Investors
  • Partnering
  • Careers
  • Company
  • Responsibility
  • Patients
  • Stories
  • Annual Report
  • Contact us
Global
LinkedIn Twitter Facebook Instagram Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

Copyright © Ipsen Pharma. All rights reserved - 2023

You are now leaving the Ipsen group website.To continue, please click on Continue?